Yao-Li Chen1, Po-Ming Chen2, Ping-Yi Lin3, Ya-Tze Hsiau4, Pei-Yi Chu5. 1. School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C. Department of General Surgery, Changhua Christian Hospital, Changhua, Taiwan, R.O.C. 2. Research Assistant Center, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C. 3. Department of General Surgery, Changhua Christian Hospital, Changhua, Taiwan, R.O.C. 4. Department of Pathology, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C. twooneboy@gmail.com chu.peiyi@msa.hinet.net. 5. Department of Pathology, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C. School of Medicine, College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan, R.O.C. National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan, R.O.C. twooneboy@gmail.com chu.peiyi@msa.hinet.net.
Abstract
UNLABELLED: Backgroung/Aim: Breast cancer resistance protein [BCRP/ATP-binding cassette subfamily G member 2 (ABCG2)] is a member of the ATP-binding cassette transporter family, used as a maker of cancer stem cells (CSCs) and thought to be responsible for drug resistance by pumping them out of cells. However, its precise role in various cancer types has been controversial, and the aim of this study was to investigate the expression of ABCG2 in hepacellular carcinoma (HCC) and relate the results to established prognostic factors. PATIENTS AND METHODS: We conducted analysis of 181 HCC and paired-match adjacent normal liver tissue by immunohistochemistry from tissue array of slides. RESULTS: The mean score for ABCG2 expression was higher in tumor than in adjacent normal liver tissue of HCC patients (p<0.001). There was a statistically significant correlation between ABCG2 expression and age, differentiation status and hepatitis B surface antigen (p=0.031, p=0.015 and p=0.033, respectively). Additionally, increased expression of ABCG2 in HCC and its statistically significant correlation with hepatitis B surface antigen was found in elderly (p=0.039), not in younger patients (p=0.518). Importantly, by using Kaplan-Meier and Cox regression analysis, overall survival in patients with high expression of ABCG2 was found reduced in elderly patients (p=0.029 and p=0.081, respectively). CONCLUSION: ABCG2 can be used as a target for the development of novel therapies in HCC. Copyright
UNLABELLED: Backgroung/Aim: Breast cancer resistance protein [BCRP/ATP-binding cassette subfamily G member 2 (ABCG2)] is a member of the ATP-binding cassette transporter family, used as a maker of cancer stem cells (CSCs) and thought to be responsible for drug resistance by pumping them out of cells. However, its precise role in various cancer types has been controversial, and the aim of this study was to investigate the expression of ABCG2 in hepacellular carcinoma (HCC) and relate the results to established prognostic factors. PATIENTS AND METHODS: We conducted analysis of 181 HCC and paired-match adjacent normal liver tissue by immunohistochemistry from tissue array of slides. RESULTS: The mean score for ABCG2 expression was higher in tumor than in adjacent normal liver tissue of HCC patients (p<0.001). There was a statistically significant correlation between ABCG2 expression and age, differentiation status and hepatitis B surface antigen (p=0.031, p=0.015 and p=0.033, respectively). Additionally, increased expression of ABCG2 in HCC and its statistically significant correlation with hepatitis B surface antigen was found in elderly (p=0.039), not in younger patients (p=0.518). Importantly, by using Kaplan-Meier and Cox regression analysis, overall survival in patients with high expression of ABCG2 was found reduced in elderly patients (p=0.029 and p=0.081, respectively). CONCLUSION:ABCG2 can be used as a target for the development of novel therapies in HCC. Copyright
Authors: Marta Alonso-Peña; Anabel Sanchez-Martin; Paula Sanchon-Sanchez; Meraris Soto-Muñiz; Ricardo Espinosa-Escudero; Jose J G Marin Journal: Cancer Drug Resist Date: 2019-09-19
Authors: Jose J G Marin; Maria J Monte; Rocio I R Macias; Marta R Romero; Elisa Herraez; Maitane Asensio; Sara Ortiz-Rivero; Candela Cives-Losada; Silvia Di Giacomo; Javier Gonzalez-Gallego; Jose L Mauriz; Thomas Efferth; Oscar Briz Journal: Cancers (Basel) Date: 2022-07-20 Impact factor: 6.575